Sanofi says Gaucher disease pill meets goal in late-stage trial

PARIS, Oct 2 (Reuters) - Sanofi's experimental pill to treat Gaucher disease, a rare inherited condition, has met its main goal in a late-stage trial, the French drugmaker said on Tuesday.

Patients treated with the drug, eliglustat tartrate, showed a statistically significant improvement in the size of their spleen after nine months compared with those who took a placebo, Sanofi said in a statement.

(Reporting by Elena Berton; Editing by Edwina Gibbs)